转换为多替拉韦/拉米夫定两药方案与继续三药或四药方案在HIV-1成人中维持病毒学抑制的疗效与安全性比较:3期非劣效SALSA随机试验第48周结果
SALSA是一项3期非劣效随机试验,纳入493例病毒学抑制的HIV-1成人,1:1随机转换为多替拉韦/拉米夫定(DTG/3TC)固定剂量复方或继续当前三药/四药方案。第48周HIV-1 RNA≥50 copies/mL的比例在DTG/3TC组为0.4%、继续方案组为1.2%,校正差异-0.8%(95%CI -2.4%至0.8%),达到非劣效;未观察到耐药,药物相关不良事件DTG/3TC组更常见(20% vs 6%)。
要点
- 转换为DTG/3TC在第48周维持病毒学抑制方面非劣于继续三药/四药方案。
- DTG/3TC组HIV-1 RNA≥50 copies/mL为0.4%(1例),继续方案组为1.2%(3例)。
- 药物相关不良事件DTG/3TC组20% vs 继续方案组6%,第24周后分别为5% vs 2%。
核心结论
- 转换为DTG/3TC在维持第48周病毒学抑制方面非劣于继续当前三药/四药方案,未观察到耐药,支持DTG/3TC的疗效、良好安全性和高耐药屏障。
研究设计与样本
- 3期、非劣效、随机(1:1,按基线第三种药物类别分层)试验,纳入HIV-1 RNA<50 copies/mL且无既往病毒学失败的成人,随机转换为每日一次DTG/3TC固定剂量复方(n=246)或继续当前三药/四药方案(n=247)。
- 主要终点为第48周HIV-1 RNA≥50 copies/mL的参与者比例(Snapshot法,意向治疗暴露人群,非劣效界值5%)。
- 共493例成人随机:39%为女性,39%年龄≥50岁,19%为非洲裔美国人/非洲裔,14%为亚洲人。
主要发现
- 第48周HIV-1 RNA≥50 copies/mL:DTG/3TC组1例(0.4%)vs 继续方案组3例(1.2%),校正差异-0.8%(95%CI -2.4%至0.8%),达到非劣效。
- 零例参与者符合确认病毒学撤药标准,因此未进行耐药检测。
- 截至第48周药物相关不良事件DTG/3TC组20% vs 继续方案组6%;第24周后分别为5% vs 2%。
- DTG/3TC组近端肾小管功能和骨转换标志物改善;两组血脂和炎症标志物变化总体较小。
关键数值与推荐
- 主要终点非劣效界值为5%,校正差异-0.8%(95%CI -2.4%至0.8%)。
- 第48周HIV-1 RNA≥50 copies/mL比例:DTG/3TC组0.4%(1例)vs 继续方案组1.2%(3例)。
- 药物相关不良事件:截至第48周DTG/3TC组20% vs 继续方案组6%;第24周后DTG/3TC组5% vs 继续方案组2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In TANGO, switching to dolutegravir/lamivudine (DTG/3TC) demonstrated long-term noninferior efficacy vs continuing tenofovir alafenamide-based regimens in treatment-experienced adults with HIV-1. The phase 3 SALSA study evaluated efficacy and safety of switching to DTG/3TC compared with continuing various 3-/4-drug current antiretroviral regimens (CARs). METHODS: Adults with HIV-1 RNA <50 copies/mL and no previous virologic failure were randomized (1:1, stratified by baseline third agent class) to switch to once-daily fixed-dose combination DTG/3TC or continue CAR (primary endpoint: proportion of participants with HIV-1 RNA ≥50 copies/mL at week 48; Snapshot, intention-to-treat-exposed population, 5% noninferiority margin). RESULTS: Overall, 493 adults (39% women; 39% aged ≥50 years; 19% African American/African heritage; 14% Asian) were randomized to switch to DTG/3TC (n = 246) or continue CAR (n = 247). At week 48, 1 (0.4%) participant in the DTG/3TC group and 3 (1.2%) in the CAR group had HIV-1 RNA ≥50 copies/mL (Snapshot), demonstrating noninferiority (adjusted difference, -0.8%; 95% CI, -2.4%, .8%). Zero participants met confirmed virologic withdrawal criteria; therefore, no resistance testing was performed. Drug-related adverse events were more frequent with DTG/3TC (20%) than CAR (6%) through week 48 but comparable post-week 24 (5% vs 2%, respectively). Proximal tubular renal function and bone turnover biomarkers improved with DTG/3TC. Both groups had generally minimal changes in lipids and inflammatory biomarkers. CONCLUSIONS: Switching to DTG/3TC was noninferior to continuing CAR for maintaining virologic suppression at week 48 with no observed resistance, supporting the efficacy, good safety, and high barrier to resistance of DTG/3TC. CLINICAL TRIALS REGISTRATION: www.clinicaltrials.gov, NCT04021290.
引用
- Llibre JM, Brites C, Cheng CY, et al. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. Clin Infect Dis. 2023. PMID: 35235656. doi:10.1093/cid/ciac130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。